Oncobiologics Q3 Earnings Call Highlights

Oncobiologics Q3 Earnings Call Highlights

Key Points FDA approval clears the way for LYTENAVA’s U.S. launch later this year as the only FDA-approved ophthalmic bevacizumab formulation for wet AMD. Management is building commercial, reimbursement, supply and medical-affairs capabilities, including plans to hire roughly 50 field personnel. Outlook Therapeutics estimates an approximately $8.5 billion U.S. anti-VEGF retina market and is targeting more than $500 million in peak annual LYTENAVA sales by 2030. First-year post-launch revenue is projected at $50 million to $75 million, with pricing expected to remain below $500 per vial. The company reported a reduced adjusted quarterly net loss of $10.9 million but had only $11.2 million in cash as of June 30. A subsequent $55 million stock-and-warrant offering is expected to provide about $51.1 million in net proceeds to fund the launch and working capital.

Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States. President and Chief Executive Officer Bob Jahr called the approval a “transformational achievement” for the company and said the focus has shifted from regulatory work to establishing commercial, reimbursement, supply and medical-affairs capabilities needed to support a launch later this year.

LYTENAVA is intended to address the established use of repackaged, off-label bevacizumab in retinal care. Jahr said retina specialists are already familiar with the bevacizumab molecule, which has been used for more than two decades, but previously lacked an FDA-approved formulation developed specifically for administration in the eye. U.S. market opportunity and launch plans The company estimates the U.S. anti-VEGF retina market totals about $8.5 billion annually. It cited an estimated 3.6 million injections of off-label repackaged bevacizumab across retinal indications in 2025, including roughly 2.2 million injections for wet AMD. Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside Jahr said the company’s base-case objective is for LYTENAVA to generate more than $500 million in peak annual U.S. sales by 2030. That forecast assumes repackaged bevacizumab remains available in the market and does not assume universal adoption, he said. During the question-and-answer session, Jahr said a disruption in the compounded or repackaged bevacizumab market could create “just under a $300 million” sales upside, although he noted that any displaced use could also shift to competing biosimilars. The company is pursuing a focused commercial model because it views the retina market as concentrated among a relatively defined group of specialists and high-volume practices. It plans to hire approximately 30 customer-facing commercial employees and about 20 field reimbursement personnel. The reimbursement team will help practices navigate coverage, acquisition, coding, inventory and patient-access considerations in the physician-administered buy-and-bill market. Jahr said the company expects to submit an application for a permanent HCPCS code by the end of the third quarter and anticipates receiving a permanent J-code in April 2027. The company said it has sufficient supply for its planned launch and is scaling its commercial supply processes. Pricing, clinical data and adoption assumptions Outlook Therapeutics expects LYTENAVA’s wholesale acquisition cost to be below $500 per vial. Jahr said pricing is intende...